Clicky

Aura Biosciences, Inc.(AURA)

Description: Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.


Keywords: Biotechnology Cancer Tumor Rare Diseases Melanoma Neoplasms Uveal Melanoma African Union

Home Page: www.aurabiosciences.com

AURA Technical Analysis

85 Bolton Street
Cambridge, MA 02140
United States
Phone: 617 500 8864


Officers

Name Title
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, Pres & Director
Ms. Julie B. Feder CFO, Sec. & Treasurer
Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA Chief Medical Officer and Head of R&D
Dr. Mark A. De Rosch Ph.D. Chief Operating Officer
Mr. Paulo Carvalho VP of Technical Operations
Mr. Joseph Lyons VP of HR
Ms. Michele Keough M.B.A. Sr. VP of Project Management and Device Supply Chain

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.8729
Price-to-Sales TTM: 0
IPO Date: 2021-10-29
Fiscal Year End: December
Full Time Employees: 52
Back to stocks